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I read with great interest Dr. Shader’s editorial that discussed vitamin C [1]. I share many of his
concerns about methodological and statistical problems in the vitamin C trials. Nevertheless, some of
my conclusions of the field are more positive.
Based on the currently published findings of randomized controlled trials (RCTs), there is no 
justification to encourage general populations of Western countries to take vitamin C regularly to 
prevent colds, cancers, or cardiovascular diseases [2,3].
Vitamin C, however, is a water-soluble antioxidant and it is possible that its administration may
have effects on people who have elevated levels of oxidative stress in their body. Oxidative stress is 
increased, for example, by heavy exertion, infections and cardiac operations [4,5]. Furthermore, the 
level of vitamin C synthesis is increased by various forms of stress in those animals that synthesize 
their own vitamin C. By analogy, larger vitamin C intakes might be beneficial for humans when they 
are under some forms of stress, as humans are unable to synthesize their own vitamin C.
In 5 RCTs involving a total of 598 marathon runners, skiers and soldiers on subarctic exercises,
vitamin C decreased the incidence of colds by 52% (95%CI 3665%) [2]. In one RCT, vitamin C 
shortened the duration of colds in adolescent male swimmers by 47% (95%CI 1480%), but had no 
effect on females [6]. In 3 RCTs with a total of 40 participants with exercise-induced 
bronchoconstriction (EIB), vitamin C reduced the post-exercise FEV1 decline by 48% (95%CI 
3364%) [7]. The participants of these 9 RCTs were under heavy physical stress and thus these 
findings cannot be extrapolated to sedentary people.
As to vitamin C and asthma, Dr. Shader wrote that I was “essentially taking a nonparametric 
view of cumulative data. Although [Hemilä] does not use an actual sign test, his implication is that 
the sheer number of positive, small sample reports prove his case.” This statement is not correct as 
the above-mentioned 48% effect on EIB was calculated with a standard parametric meta-analysis 
approach [7]. I had indeed challenged the conclusions of the Cochrane review on vitamin C and 
asthma on statistical grounds since there were severe errors in the extraction of data and in the 
statistical analyses such as using the un-paired t-test for paired data [8,9].
Our Cochrane meta-analysis of over two dozen placebo-controlled trials calculated that ≥1 
g/day vitamin C shortens the duration of colds in children by 18% (95%CI 927%) and in adults by 
8% (95%CI 412%) [2,4]. Two RCTs found linear dose responses in the effect on cold duration by up 
to 6 and 8 g/day doses of vitamin C, with colds being shortened by some 20% on the higher dose [4].
Still higher therapeutic dosages might lead to greater benefits, but have not been investigated yet. 
Dr. Shader criticized vitamin C and common cold trials for various reasons, yet I do not 
consider some of his comments valid, nor do I agree with several other comments. I do agree fully 
with Dr. Shader’s description of the common cold being a heterogenous pathological entity. 
However, that does not refute the benefits of vitamin C in the controlled trials mentioned above. If a 
trial investigates the effects of vitamin C on an experimental rhinovirus infection, it is not clear how 
far the results can be generalized to the common colds in the general population. However, the 
primary focus of our Cochrane review was on colds in the general population and therefore the 
findings seem relevant even though colds are heterogeneous [2]. Importantly, since the trials used 
concurrent controls, the variation in common cold incidence over years and seasons did not bias the 
comparisons. Finally, the vitamin C was ascorbic acid and the placebo was citric acid in most of the 
trials in the Cochrane review. Therefore, a placebo effect caused by taste difference in those studies 
is a debatable explanation for the differences between the vitamin C and placebo groups [2].
The reported clinical effects of vitamin C are not limited to the common cold and EIB. 
Fourteen RCTs examined the effects of vitamin C on post-operative AF (POAF) in cardiac surgery 
patients. Vitamin C had no effect on POAF in 5 trials carried out in the USA. However, vitamin C 
decreased the incidence of POAF on average by 44% (95%CI 3353%) in 9 trials conducted in Iran, 
Greece, Russia, and Slovenia [5]. In a cardioversion trial carried out in Greece, vitamin C decreased 
the risk of AF recurrence by 87% (95%CI 898%) [5]. Finally, one meta-analysis of patients with 
atherosclerosis or heart failure reported that vitamin C improved endothelial function [10], another 
meta-analysis revealed that vitamin C reduced blood pressure [11], and a third showed that vitamin C
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decreased the risk of contrast-induced acute kidney injury in patients undergoing coronary 
angiography [12]. Thus, vitamin C may have therapeutic effects in certain special conditions, 
although regular vitamin C supplementation does not seem beneficial for ordinary people [2,3].
Vitamin C field is indeed complex and confusing. It is puzzling that the many positive RCTs on
vitamin C have been largely ignored by mainstream medicine, which may be explained by a few 
historical factors [4]. For instance, the substance vitamin C was identified as the etiological 
explanation for scurvy, which was considered a disease of the connective tissues. It may have seemed
irrational to consider that a substance that was assumed to participate ‘only’ in collagen metabolism 
might also have effects on infections, pulmonary functions, and cardiac disorders. However, the 
biochemistry of vitamin C is complex and not limited to collagen metabolism [4,5]. 
I do agree with Dr. Shader that more research on vitamin C is needed. On the other hand, 
published RCTs in general give us the average effect of a treatment, but there are individual 
variations around the avearge. As to the self-medication anecdote alluded to by Dr Shader, an 
analogy is the individual level experimentation that is usual practice in clinical therapeutics to figure 
out whether, say, a particular triptan is effective for a certain patient with migraine. The same 
reasoning goes for vitamin C. Vitamin C is an inexpensive essential nutrient and there is little 
evidence of adverse effects of high doses [13]. It seems reasonable, therefore, to encourage common 
cold patients to test for themselves whether vitamin C might benefit them at the individual level [2].  
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